Psych drugs slated for AC review
Executive Summary
Wyeth's antidepressant desvenlafaxine (DVS-233) will undergo evaluation by FDA's Psychopharmacologic Drugs Advisory Committee Sept. 8. Wyeth has said the launch of the Effexor (venlafaxine) follow-on may be delayed while it studies lower doses and resolves manufacturing problems (1"The Pink Sheet" July 17, 2006, p. 11). The meeting will be held at the Hilton in Gaithersburg, Md., beginning at 8 a.m. FDA had announced the committee would review Johnson & Johnson's extended-release paliperidone, an active metabolite of the firm's atypical antipsychotic Risperdal (risperidone), on Sept. 7, but J&J says the meeting has been cancelled...